Position in EXEL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$936,031
-$66,755 QoQ
Shares Held
21,824
-4.6% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026EP Wealth Advisors, LLC holds $13,173,188 across 19 Biotechnology names. EXEL ranks #6 (7.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
8,637 | $3,856,765 | |
| 2 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
38,406 | $2,408,056 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,444 | $1,115,692 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
5,522 | $1,043,934 | |
| 5 | INCY |
Incyte Corp
|
10,812 | $1,017,625 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
21,824 | $936,031 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
8,542 | $552,069 | |
| 8 | RPRX |
Royalty Pharma plc
|
9,665 | $463,630 |
All Filings in EXEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $936,031 | 21,824 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,002,786 | 22,879 | Shares | Sole | 2026-02-18 | |
| 2025-06-30 | $853,124 | 19,354 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $729,686 | 19,764 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $439,360 | 13,194 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $306,313 | 11,804 | Shares | Sole | 2024-11-15 | |
| No filing history on record for this holder in this stock. | ||||||